MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 1087-1090

  De Paoli, Lorenzo ^a   Cerri, Michaela ^a   Monti, Sara ^a   Rasi, Silvia ^a   Spina, Valeria ^a   Bruscaggin, Alessio ^a   Greco, Mariangela ^a   Ciardullo, Carmela ^a   Famà, Rosella ^a   Cresta, Stefania ^a   Maffei, Rossana ^b   Ladetto, Marco ^c   Martini, Maurizio ^d   Laurenti, Luca ^d   Forconi, Francesco ^e,f   Marasca, Roberto ^b   Larocca, Luigi M ^d   Bertoni, Francesco ^g   Gaidano, Gianluca ^a   Rossi, Davide ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF SIENA   (Italy)

^g INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC LYMPHATIC LEUKEMIA; COPY NUMBER VARIATION; EXON; GENE; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; LETTER; MAX GENE ASSOCIATED GENE; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; GENE DELETION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84876275925     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.723706     Document Type: Letter

References (14)

1. Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101-4107.
2. Fangazio M, De Paoli L, Rossi D, et al. Predictive markers and driving factors behind Richter syndrome development. Expert Rev Anticancer Ter 2011;11:433-442.
3. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391-3401.
4. Hurlin PJ, Steingrìmsson E, Copeland NG, et al. Mga, a dual-specif city transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J 1999;18:7019-7028.
5. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009; 15: 4415-4422.
6. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
7. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
8. Rossi D, Bruscaggin A, Spina V, et al. Mutationsof theSF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
9. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521-529.
10. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.
11. Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA prof ling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011;154:590-599.
12. Zhang W, Kater AP, Widhopf GF 2nd, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) inf uence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010;107:18956-18960.
13. Huh YO, Lin KI, Vega F, et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008;142:36-44.
14. Put N, Van Roosbroeck K, Konings P, et al. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol 2012; 91:863-873.